Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Mar 21, 2017; 23(11): 2023-2028
Published online Mar 21, 2017. doi: 10.3748/wjg.v23.i11.2023
Table 2 Clinical features and treatment of 16 patients with ipilimumab-mediated enterocolitis n (%)
Onset of diarrhea
After 1 dose of ipilimumab3 (19)
After 2 doses of ipilimumab7 (43)
After 3 doses of ipilimumab3 (19)
After 4 doses of ipilimumab3 (19)
Diarrhea details
Number of bowel movements/day, median (range)6 (5-12)
Grade 2 diarrhea9 (56)
Grade 3 diarrhea7 (44)
Grade 4/5 diarrhea0
Associated symptoms
Abdominal pain10 (63)
Nausea or vomiting3 (19)
Fever2 (13)
Anorexia2 (13)
Endoscopic findings
Mucosal erythema, edema, or erosions only6 (43)
Ulcers8 (57)
Treatment of diarrhea
High dose corticosteroids16 (100)
Infliximab9 (56)